Vitamin E Should NOT Be Used for Peyronie's Disease
Do not prescribe vitamin E for Peyronie's disease—there is no convincing evidence for its efficacy, and it delays potentially effective treatments. The 2015 AUA Guideline explicitly recommends against oral vitamin E therapy for Peyronie's disease 1.
Why Vitamin E Doesn't Work
The evidence is clear and consistent:
The AUA Guideline (2015) provides a Moderate Recommendation (Evidence Grade B) specifically stating clinicians should NOT offer oral vitamin E for Peyronie's disease 1. This recommendation prioritizes avoiding therapies without proven efficacy that postpone effective treatments and waste patient time and resources.
The highest quality randomized controlled trial (2007) with 236 patients found no significant improvement in pain, penile curvature, or plaque size with vitamin E (300 mg twice daily) compared to placebo over 6 months 2. Pain decreased in 60.4% with vitamin E versus 59.2% with placebo (p=0.1), and curvature reduction was 18.9% versus 18.4% (p=0.09)—essentially identical outcomes.
The Evidence Against Vitamin E
While some older studies suggested benefit:
- A 2013 study 3 showed plaque reduction with vitamin E as part of multimodal therapy
- A 2003 study 4 showed improvement when combined with colchicine
These studies are contradicted by the definitive 2007 RCT 2 and superseded by the 2015 AUA Guideline 1, which reviewed all available evidence and concluded vitamin E should not be offered.
What Actually Works
For patients with stable Peyronie's disease, penile curvature 30-90°, and intact erectile function: Intralesional collagenase clostridium histolyticum combined with modeling is the evidence-based treatment (Moderate Recommendation, Evidence Grade B) 1.
For pain management in active disease: Non-steroidal anti-inflammatory medications may be offered 1.
Critical Pitfall to Avoid
Using vitamin E delays access to proven therapies and gives false hope. Even though vitamin E has minimal adverse effects at typical doses (the upper limit is 1000 mg/day 5), prescribing ineffective treatment constitutes a moderate burden by postponing effective interventions and failing to alleviate patient distress 1.
The standard vitamin E dosage for general nutritional needs is 15 mg/day 5, but this is irrelevant for Peyronie's disease where vitamin E has no therapeutic role regardless of dose.